1.
EGFR与KRAS基因突变亚组分析
Subgroup analysis of EGFR and KRAS mutation status
| Clinical characteristics | n | EGFR gene (n=394)* | P | KRAS gene (n=393)** | P | ||
| Mutation | Wild type | Mutation | Wild type | ||||
| *One sample not tested for EGFR mutations; **Two samples not tested for KRAS mutations; EGFR: epidermal growth factor receptor. | |||||||
| Gender | ＜0.001 | 0.181 | |||||
| Male | 211 (53.4%) | 78 (37.1%) | 132 (62.9%) | 19 (9.1%) | 190 (90.9%) | ||
| Female | 184 (46.6%) | 114 (62.0%) | 70 (38.0%) | 10 (5.4%) | 174 (94.6%) | ||
| Age (yr) | 20-82 (57.91±0.558) | 0.265 | 0.519 | ||||
| ＜65 | 284 (71.9%) | 143 (50.5%) | 140 (49.5%) | 23 (8.1%) | 260 (91.9%) | ||
| ≥65 | 111 (28.1%) | 49 (44.1%) | 62 (55.9%) | 6 (5.5%) | 104 (94.5%) | ||
| Smoking history | ＜0.001 | 0.155 | |||||
| Non-smoker | 215 (54.4%) | 133 (61.9%) | 82 (38.1%) | 11 (5.1%) | 204 (94.9%) | ||
| Light-smoker | 57 (14.4%) | 22 (38.6%) | 35 (61.4%) | 5 (8.9%) | 51 (91.1%) | ||
| Smoker | 123 (31.1%) | 37 (30.3%) | 85 (69.7%) | 13 (10.7%) | 109 (89.3%) | ||
| TNM stage | 0.070 | 0.736 | |||||
| Ⅰ | 52 (13.2%) | 33 (64.7%) | 18 (35.3%) | 3 (5.8%) | 49 (94.2%) | ||
| Ⅱ | 16 (4.1%) | 7 (43.8%) | 9 (56.2%) | 2 (12.5%) | 14 (87.5%) | ||
| Ⅲ | 64 (16.2%) | 21 (32.8%) | 43 (67.2%) | 6 (9.4%) | 58 (90.6%) | ||
| Ⅳ | 263 (66.6%) | 131 (49.8%) | 132 (50.2%) | 18 (6.9%) | 243 (93.1%) | ||
| Biopsy type | 0.744 | 0.954 | |||||
| Incisional | 173 (43.8%) | 86 (50.0%) | 86 (50.0%) | 15 (8.7%) | 158 (91.3%) | ||
| Bronchoscopic | 71 (18.0%) | 34 (47.9%) | 37 (52.1%) | 4 (5.8%) | 65 (94.2%) | ||
| Core biopsy | 82 (20.8%) | 38 (46.3%) | 44 (53.7%) | 5 (6.1%) | 77 (93.9%) | ||
| Localisation | 50 (12.7%) | 24 (48.0%) | 26 (52.0%) | 4 (8.0%) | 46 (92.0%) | ||
| Pleural | 11 (2.8%) | 4 (36.4%) | 7 (63.6%) | 1 (9.1%) | 10 (90.9%) | ||
| Cells | 7 (1.8%) | 5 (71.4%) | 2 (28.6%) | 0 (0) | 7 (100%) | ||
| Mediastinum | 1 (0.3%) | 1 (100%) | 0 (0) | 0 (0) | 1 (100%) | ||